Name: In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells (Video) | JoVE Journal
Uploaded: 2025-03-07T12:40:00.000+00:00
Duration: 6 min 38 s
Description: Explore in vitro modeling of Down syndrome neurogenesis using human iPSCs. This protocol reveals biphasic cell cycle defects causing impaired neuron generation, offering insights for therapeutic development.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

The authors thank Prof. Stuart H. Orkin for providing us with a pair of Down syndrome and isogenic euploid hiPSCs. The authors are also thankful to the National Centre for Cell Science (BRIC-NCCS), Pune, for providing the funding to carry out this work.

The following protocol was followed with two pairs of Down syndrome and its isogenic euploid human iPSCs. One pair was generated using the retroviral mediated delivery method of reprogramming19, and a second pair (NSi003-A and NSi003-B) was generated using the non-integrating Sendai virus delivery method20. The protocol broadly consists of two stages: The neurogenic stage (Stage 1) and the neural differentiation stage (Stage 2). Further, two phases based on the differences in the proliferation of Down syndrome and isogenic euploid cell lines, i.e., the Early and Late phases, are observed in the neurogenic stage. The details of the reagents, media, and equipment used in this study are listed in the Table of Materials.
1. Down syndrome hiPSCs and isogenic euploid hiPSCs culture and maintenance
<ol>
	<li>Feeder plating for hiPSCs 
	NOTE: Feeder quality and density are extremely important for good quality of human iPSCs culture.
	<ol>
		<li>Add 2 mL of 0.1% gelatin to coat a 6-well plate for at least 1-2 h at 37 &#176;C before seeding with feeder cells.</li>
		<li>Keep the gelatin-coated plate at room temperature in the cell culture hood for at least 30 min before plating the cells.</li>
		<li>Warm mouse embryonic fibroblast (MEF) media to be used for revival in bead bath/water bath.</li>
		<li>Aliquot 5 mL of MEF media into a 15 mL centrifuge tube.</li>
		<li>Take out a vial of feeder cells from the liquid nitrogen tank (LN2 tank). 
		NOTE: Feeder cells were derived by treating E13.5 Mouse embryonic fibroblasts with 10 &#181;g/mL Mitomycin C for 3 h followed by 2-3 times washing with DPBS18. Feeder cells can be used directly or frozen in an LN2 tank for future use. All mice were used after Institutional Animal Ethics Committee approval.</li>
		<li>Keep the vial at 37 &#176;C in the water bath using a floating rack until a small piece of ice remains.</li>
		<li>Take the vial inside the biosafety cabinet and sterilize it with alcohol before putting it inside the biosafety cabinet.</li>
		<li>Add 1 mL of warm MEF media (see Table of Materials) drop by drop.</li>
		<li>Take out the media from the vial gently and pour drop by drop into a 15 mL centrifuge tube containing MEF media.</li>
		<li>Centrifuge at room temperature for 5 min at 200 x g.</li>
		<li>Aspirate the supernatant using a vacuum aspiration system (VAS).</li>
		<li>Add 1 mL of MEF medium and gently pipette up and down 3-4 times.</li>
		<li>Take the cell count using a hemocytometer. Dead cells were excluded using Trypan Blue.</li>
		<li>Plate 3.1-3.3 x 105 live feeder cells per well of a 6-well plate or 2 x 106 cells per 6-well plate in MEF medium.</li>
		<li>Keep the plate inside the CO2 incubator at 37&#160;&#176;C with 85% humidity overnight. Shake the plate inside the CO2 incubator front-back and sideways 2-3 times to achieve a homogenous distribution of feeder cells.</li>
	</ol>
	</li>
	<li>Revival of Down syndrome hiPSCs and isogenic Euploid hiPSCs 
	NOTE: Warm the required volume of hiPSC media in a 37 &#176;C bead bath. 
	&#8203;Human induced pluripotent stem cells (hiPSC) revival medium: Freshly add 25 ng/mL Basic Fibroblast Growth Factor (bFGF) and 10 &#181;M Rock inhibitor (RI) (Y-27632 2HCl) in hiPSC medium.
	<ol>
		<li>Remove MEF media from the feeders well and give one wash to the feeders by gently adding 1 mL/well of warm DMEM/F12 from the sides of the well. Aspirate the medium and add 2 mL/well warm hiPSC revival medium. Leave the plate inside the incubator for at least 2 h before plating hiPSCs.</li>
		<li>Take out a vial of hiPSCs.</li>
		<li>Keep the vial on a floating rack in a 37 &#176;C water bath until a small piece of ice remains.</li>
		<li>Before taking the vial inside the biosafety cabinet, sterilize it with 70% alcohol.</li>
		<li>Add 1 mL of warm hiPSC revival medium.</li>
		<li>Take out the media from the vial gently and pour drop by drop into a 15 mL centrifuge tube containing 5 mL of hiPSCs revival media.</li>
		<li>Centrifuge at room temperature for 2 min at 100 x g.</li>
		<li>Aspirate the supernatant using VAS and dislodge the pellet by gently tapping the tube.</li>
		<li>Pour 500 &#181;L of hiPSC medium with 10 &#181;M of RI and pour over the feeder plate containing hiPSC revival medium. Label the plate with the cell&#39;s name, passage number, researcher&#39;s name, and date.</li>
		<li>Observe the hiPSC colonies under an inverted microscope at 4x magnification; there should be clumps of cells.</li>
		<li>While keeping the plate inside the CO2 incubator, shake the plate front-back and sideways 2-3 times to achieve a homogenous distribution of cells. Do not disturb the plate for 24 h.</li>
		<li>The following day, some colonies may look adhered to feeders, and some would be floating. Without aspirating any media, add fresh hiPSCs medium supplemented with 25 ng/mL bFGF and 10 &#181;M of RI.</li>
		<li>On the second day after revival, most of the colonies would be attached to the surface. Change complete medium with hiPSC medium with 25 ng/mL bFGF. In the following days, hiPSC colonies will be visible. 
		NOTE: It takes at least a week for hiPSCs to revive and make colonies with smooth, well-defined borders, uniform cell morphology, and a dense colony center.</li>
	</ol>
	</li>
	<li>Passaging Down syndrome hiPSCs and isogenic Euploid hiPSCs on feeders 
	NOTE: All the reagents should be warm before starting. Avoid over-pipetting of cells. Handle cells very gently.
	<ol>
		<li>Passage hiPSCs when most of the colonies start merging into each other or when there is the emergence of too many differentiated colonies. Generally, splitting needs to be performed within 5-7 days after the first passage.</li>
		<li>Revive a vial of feeders one day before splitting.</li>
		<li>Give one wash to feeders with 1 mL/well of warm DMEM/F12 and add 2 mL/well of warm hiPSCs medium supplemented with 25 ng/mL bFGF. Leave the plate inside the CO2 incubator at 37 &#176;C for at least 2 h before plating hiPSCs.</li>
		<li>Observe the plate with hiPSCs for differentiated colonies and remove the differentiated colony by scrapping using a 200 &#181;L pipette under a stereomicroscope.</li>
		<li>Give one wash to hiPSCs with 1 mL/well warm DMEM/F12.</li>
		<li>Pour 1 mL/well of 1 mg/ml collagenase solution. Keep the plate inside the incubator for 8-10 min, and then observe under an inverted microscope for the loose edges of colonies.</li>
		<li>Aspirate the collagenase and give 2 washes of DMEM/F12. Then add 1 mL/well hiPSC Medium.</li>
		<li>Gently cut colonies horizontally and vertically 8-10 times in a well using the tip of a 2 mL syringe. Observe the colonies under an inverted microscope to check if most of the colonies have been cut to the appropriate size.</li>
		<li>If colonies are cut sufficiently, gently lift the colonies using a cell lifter.</li>
		<li>Gently pipette the colonies in the well using a 1 mL tip, 5-8 times, depending on the size of the colonies.</li>
		<li>Collect all the cells into a 15 mL centrifuge tube and centrifuge at room temperature for 2 min at 100 x g.</li>
		<li>Aspirate the supernatant gently using a pipette, dislodge the cell pellet by gently tapping the tube, and add 200 &#181;L of hiPSC medium with 25 ng/mL bFGF and 10 &#181;M of RI. Pipette 2-3 times with the 200 &#181;L pipette and add 300 &#181;L more hiPSC medium with 25 ng/mL bFGF and 10 &#181;M of RI.</li>
		<li>Now gently plate these cells over the feeders containing hiPSC medium + 25 ng/mL bFGF. One well can be split into 1:2 or 1:3, depending on the number of colonies present after removing differentiated colonies. Label the plate with the cell&#39;s name, passage number, researcher&#39;s name, and date.</li>
		<li>While keeping the plate inside the CO2 incubator, shake the plate front-back and sideways 2-3 times to achieve a homogenous distribution of cells.</li>
		<li>The next day, give one gentle wash with warm DMEM/F12 and add 2.5 mL of hiPSC medium with 25 ng/mL bFGF.</li>
	</ol>
	</li>
	<li>Freezing Down syndrome hiPSCs and isogenic Euploid hiPSCs from feeders 
	NOTE: Over-pipetting of human iPSCs should be avoided during the freezing procedure.
	<ol>
		<li>Split hiPSCs when they are still in their log phase, i.e., 4-5 days after passage.</li>
		<li>Observe the plate with hiPSCs for differentiated colonies and remove the differentiated colonies using a 200 &#181;L pipette under a stereomicroscope.</li>
		<li>Give one wash to hiPSCs with 1 mL/well warm DMEM/F12.</li>
		<li>Add 1 mL/well of 1 mg/mL collagenase solution. Keep the plate inside the incubator for 8-10 min, and then observe under an inverted microscope for lifting edges of colonies.</li>
		<li>Aspirate the collagenase and give 2 washes of DMEM/F12. Then add 1 mL/well hiPSC Medium.</li>
		<li>Gently lift the colonies using a cell lifter.</li>
		<li>Gently pipette the colonies in the well using a 1 mL tip 5-8 times, depending on the size of the colonies.</li>
		<li>Collect all the cells into a 15 mL centrifuge tube and centrifuge at room temperature for 2 min at 100 x g.</li>
		<li>Aspirate the supernatant gently using a pipette, dislodge the cell pellet by gently tapping on the tube, and add 1 mL of hiPSC Medium without antibiotic supplemented with 25 ng/mL bFGF as per the number of wells. Dispense cells into cryovials.</li>
		<li>Add hiPSC Medium without antibiotic supplemented with 25 ng/mL bFGF and 20% DMSO in the cryovials to achieve a 10% final concentration of DMSO.</li>
		<li>Put the cryovials in a frosty having an isopropanol bath to provide slow freezing.</li>
		<li>Keep the frosty at -80 &#176;C overnight. Transfer the vials the next day to the LN2 tank.</li>
	</ol>
	</li>
</ol>
2. Neuronal differentiation
NOTE: Preparation of Feeder-Conditioned Medium (FCM): Use a T-75 flask and plate 4 x 106 feeder cells per flask. Next day, add 40 mL of hiPSC medium with 4 ng/mL bFGF. Collect for 7 days. Store each day tube at -20&#160;&#176;C for up to 1 month. Coat a 15 cm dish with 10 mL of 0.1% gelatin at 37 &#176;C for at least 2 h before dissociating cells. Coat a 6-well plate with hESC-qualified basement membrane matrix (hereafter called &#34;qualified matrix&#34;) 1 day before dissociating cells. When dissociating cells in the whole protocol, add 10 &#181;M of RI to the cell detachment solution (see Table of Materials), DPBS, and plating media (FCM supplemented with 25 ng/mL bFGF). Prepare fresh feeder-conditioned medium (FCM) for every differentiation. Avoid over-pipetting of hiPSCs.
<ol>
	<li>Day In vitro (DIV) 2: Making single cells and seeding of hiPSCs for neurodifferentiation
	<ol>
		<li>Add 10 &#181;M of RI into hiPSC media supplemented with 25 ng/mL bFGF, DPBS, cell detachment solution, and Feeder Conditioned Medium supplemented with 25 ng/mL bFGF. Warm all these reagents at 37 &#176;C.</li>
		<li>Take a 6-well plate of iPSCs on feeders, remove differentiated colonies, and add fresh hiPSC media supplemented with 25ng/mL bFGF and 10 &#181;M of RI. Keep the plate for 2 h in the incubator.</li>
		<li>Take out the iPSCs plate after 2 h and give one wash with DPBS without Ca++ and Mg++.</li>
		<li>Add 1 mL/well cell detachment solution (+ 10 &#181;M of RI) and keep the plate inside the CO2 incubator for 12-14 min.</li>
		<li>After 12-14 min, observe the cells under an inverted microscope; most of the cells start detaching from the plate. If some cells still adhere, gently tap the plate from the sides.</li>
		<li>Dilute cell detachment solution by adding 3 mL/well DPBS with Ca++ and Mg++ (+ 10 &#181;M of RI). Using a 5 mL pipette, do 2-3 times gentle pipetting, avoiding bubbles to break clumps.</li>
		<li>Pass cells through a 40 &#181;M strainer.</li>
		<li>Collect the cells into a 50 mL centrifuge tube.</li>
		<li>Centrifuge at room temperature for 5 min at 200 x g and aspirate media gently using VAS.</li>
		<li>Resuspend the cells in 10 mL of hiPSC medium (+ 25 ng/mL bFGF + 10 &#181;M of RI). Add cells onto a 0.1% gelatin-coated 15 cm dish for 1.5 h to remove feeders since feeders have preferential adhesion to the gelatin-coated surface compared to hiPSCs.</li>
		<li>After 1.5 h, gently collect the media with cells and centrifuge at room temperature for 5 min at 200 x g. Aspirate media using VAS.</li>
		<li>Resuspend the cells in 1 mL of FCM (+ 25 ng/mL bFGF + 10 &#181;M of RI) and take the cell count.</li>
		<li>Using FCM (+ 25 ng/mL bFGF + 10 &#181;M of RI), make cell suspension of 30,000-50,000 cells/mL and seed 5 mL cell suspension/60 mm plate or 2 mL/well of 6-well plate or 500 &#181;L/well of 24-well plate. Plates should be coated with a qualified matrix (see Table of Materials).</li>
	</ol>
	</li>
	<li>DIV 0: (~48 h later): Change feeder-conditioned medium to NPC media (DDM + B27 without Vitamin A + N2) (see the Table of Materials).</li>
	<li>DIV 2: Add NPC medium with 0.125 &#181;M of Dorsomorphin every alternate day till DIV 18.</li>
	<li>DIV 18: Add NPC media without Dorsomorphin and replenish every alternate day till DIV 28.</li>
	<li>DIV 28-30: Making single cells and seeding of NPCs for Stage 2
	<ol>
		<li>On DIV 28, take out the plate (containing NPCs), and replace the media with NPC media (+ 10 &#181;M of RI). Put the plate in the CO2 incubator for 2 h.</li>
		<li>After 2 h, aspirate the media and give one wash with DPBS (without Ca++ and Mg++).</li>
		<li>Add 1 mL/well cell detachment solution (+ 10 &#181;M of RI) and keep the plate inside the incubator for 14 min.</li>
		<li>After 14 min, observe the cells under an inverted microscope at 4x. Most of the cells start detaching from the plate. If some cells still adhere, gently tap the plate from the sides.</li>
		<li>Dilute the cell detachment solution by adding 3 mL/well DPBS with Ca++ and Mg++ (+ 10 &#181;M of RI). Using a 5 mL pipette, do 2-3 times gentle pipetting, avoiding bubbles to break clumps.</li>
		<li>Pass through 40 &#181;M strainer placed onto a 50 mL centrifuge tube.</li>
		<li>Centrifuge at room temperature for 5 min at 200 x g. Aspirate media gently using VAS.</li>
		<li>Resuspend the cells in DDM + B27 with vitamin A (+ 10 &#181;M of RI).</li>
		<li>Count the live cells using trypan blue with a hemocytometer.</li>
		<li>Seed 50,000 cells/well on a qualified matrix-coated plate (1x) of the 48-well plate.</li>
	</ol>
	</li>
	<li>DIV 33: Change medium to neural differentiation medium (see the Table of Materials). Change the medium every 5 days. Keep replenishing media until DIV 85/90.</li>
</ol>
3. Immunocytochemistry (ICC)
NOTE: Add enough buffer at all stages to cover cells and avoid drying of the well while aspirating during the washing stage.
<ol>
	<li>Take out the differentiated cell plate outside the cell culture area.</li>
	<li>Aspirate the media and give a DPBS wash.</li>
	<li>For fixation, add 1 mL of 4% paraformaldehyde (PFA) to the cells. Cover the plate with aluminum foil and place it on a rocker shaker at 37 &#176;C for 30 min.</li>
	<li>Aspirate PFA and give three washes each of 15 min with DPBS (without Ca++ and Mg++).</li>
	<li>Add blocking buffer (3% BSA + 5% Donkey Serum (or sera from host animal of secondary antibody) + 0.2% Triton-X in DPBS) for 1 h at room temperature.</li>
	<li>Add 250 &#181;L/well of primary antibodies [Ki67 (1: 100 dilution), TUBB3 (1: 500 dilution), PAX6 (1: 100)] and incubate overnight at 4 &#176;C on a rocker shaker. Dilution was done in a blocking solution.</li>
	<li>Wash three times with DPBS after primary antibody incubation.</li>
	<li>Add 250 &#181;L/well of secondary antibody (diluted 1: 250 in 3% BSA + 0.2% Triton-X in DPBS) for 1 h at room temperature.</li>
	<li>Wash 3 times with DPBS after secondary antibody incubation.</li>
	<li>Add DAPI (1: 1000 dilution of 5 mg/mL stock in DPBS) for 15 min at room temperature. Wash three times with DPBS. Leave the last wash in the culture plate and observe under the microscope.</li>
</ol>
4. Image acquisition and analysis
<ol>
	<li>Capture images using the fluorescence microscope at 20x resolution.</li>
	<li>Capture images of Ki67, as well as TUBB3 staining images using an excitation filter of 540 nm, PAX6 using an excitation filter of 488 nm, and DAPI images using an excitation filter of 358 nm.</li>
	<li>Capture images from ten different random fields for analysis.</li>
	<li>Analyze ICC images using ImageJ software.</li>
	<li>For TUBB3 and PAX6 analysis, perform thresholding all the images for the red and green signals, respectively, and blue signal intensity for DAPI. The mean intensity of the red pixels of TUBB3 and green pixels of PAX6 were normalized with the mean intensity of the blue pixels of DAPI.</li>
	<li>For Ki67 analysis, count the cells using the automated cell counter feature in ImageJ software. Normalize the number of Ki67-positive cells with the number of DAPI-positive cells.</li>
	<li>Perform statistical analysis using statistics and graphing software by comparing the two groups using unpaired t-tests. Data should be expressed as mean &#177; SEM from three independent experiments. A p-value of less than 0.05 is considered statistically significant.</li>
</ol>

<ol><li>Chapman, R. S., Hesketh, L. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Behavioral+phenotype+of+individuals+with+Down+syndrome%5BTitle%5D)+AND+%22Ment+Retard+Dev+Disabil+Res+Rev%22%5BJournal%5D)">Behavioral phenotype of individuals with Down syndrome.</a> Ment Retard Dev Disabil Res Rev. 6 (2), 84-95 (2000).</li>
<li>Haydar, T. F., Reeves, R. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Trisomy+21+and+early+brain+development%5BTitle%5D)+AND+%22Trends+Neurosci%22%5BJournal%5D)">Trisomy 21 and early brain development.</a> Trends Neurosci. 35 (2), 81-91 (2012).</li>
<li>Wisniewski, K. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Down+syndrome+children+often+have+brain+with+maturation+delay%2C+retardation+of+growth%2C+and+cortical+dysgenesis%5BTitle%5D)+AND+%22Am+J+Med+Genet+Suppl%22%5BJournal%5D)">Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis.</a> Am J Med Genet Suppl. 7, 274-281 (1990).</li>
<li>Guidi, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Neurogenesis+impairment+and+increased+cell+death+reduce+total+neuron+number+in+the+hippocampal+region+of+fetuses+with+Down+syndrome%5BTitle%5D)+AND+%22Brain+Pathol%22%5BJournal%5D)">Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome.</a> Brain Pathol. 18 (2), 180-197 (2008).</li>
<li>Lott, I. T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Neurological+phenotypes+for+Down+syndrome+across+the+life+span%5BTitle%5D)+AND+%22Prog+Brain+Res%22%5BJournal%5D)">Neurological phenotypes for Down syndrome across the life span.</a> Prog Brain Res. 197, 101-121 (2012).</li>
<li>Stagni, F., Giacomini, A., Emili, M., Guidi, S., Bartesaghi, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Neurogenesis+impairment%3A+An+early+developmental+defect+in+Down+syndrome%5BTitle%5D)+AND+%22Free+Radic+Biol+Med%22%5BJournal%5D)">Neurogenesis impairment: An early developmental defect in Down syndrome.</a> Free Radic Biol Med. 114, 15-32 (2018).</li>
<li>Golden, J. A., Hyman, B. T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+of+the+superior+temporal+neocortex+is+anomalous+in+trisomy+21%5BTitle%5D)+AND+%22J+Neuropathol+Exp+Neurol%22%5BJournal%5D)">Development of the superior temporal neocortex is anomalous in trisomy 21.</a> J Neuropathol Exp Neurol. 53 (5), 513-520 (1994).</li>
<li>Gupta, M., Dhanasekaran, A. R., Gardiner, K. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mouse+models+of+Down+syndrome%3A+Gene+content+and+consequences%5BTitle%5D)+AND+%22Mamm+Genome%22%5BJournal%5D)">Mouse models of Down syndrome: Gene content and consequences.</a> Mamm Genome. 27 (11-12), 538-555 (2016).</li>
<li>Wu, Y., West, N. R., Bhattacharyya, A., Wiseman, F. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cell+models+for+Down+syndrome-Alzheimer%27s+disease+research%5BTitle%5D)+AND+%22Neuronal+Signal%22%5BJournal%5D)">Cell models for Down syndrome-Alzheimer's disease research.</a> Neuronal Signal. 6 (1), NS20210054(2022).</li>
<li>Zhao, X., Bhattacharyya, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+models+are+needed+for+studying+human+neurodevelopmental+disorders%5BTitle%5D)+AND+%22Am+J+Hum+Genet%22%5BJournal%5D)">Human models are needed for studying human neurodevelopmental disorders.</a> Am J Hum Genet. 103 (6), 829-857 (2018).</li>
<li>Takahashi, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Induction+of+pluripotent+stem+cells+from+adult+human+fibroblasts+by+defined+factors%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Induction of pluripotent stem cells from adult human fibroblasts by defined factors.</a> Cell. 131 (5), 861-872 (2007).</li>
<li>Takahashi, K., Yamanaka, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Induction+of+pluripotent+stem+cells+from+mouse+embryonic+and+adult+fibroblast+cultures+by+defined+factors%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.</a> Cell. 126 (4), 663-676 (2006).</li>
<li>Briggs, J. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Integration-free+induced+pluripotent+stem+cells+model+genetic+and+neural+developmental+features+of+Down+syndrome+etiology%5BTitle%5D)+AND+%22Stem+Cells%22%5BJournal%5D)">Integration-free induced pluripotent stem cells model genetic and neural developmental features of Down syndrome etiology.</a> Stem Cells. 31 (3), 467-478 (2013).</li>
<li>Hibaoui, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Modeling+and+rescuing+neurodevelopmental+defect+of+Down+syndrome+using+induced+pluripotent+stem+cells+from+monozygotic+twins+discordant+for+trisomy+21%5BTitle%5D)+AND+%22EMBO+Mol+Med%22%5BJournal%5D)">Modeling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21.</a> EMBO Mol Med. 6 (2), 259-277 (2014).</li>
<li>Shi, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+human+stem+cell+model+of+early+Alzheimer%27s+disease+pathology+in+Down+syndrome%5BTitle%5D)+AND+%22Sci+Transl+Med%22%5BJournal%5D)">A human stem cell model of early Alzheimer's disease pathology in Down syndrome.</a> Sci Transl Med. 4 (124), 124ra29(2012).</li>
<li>Weick, J. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Deficits+in+human+trisomy+21+iPSCs+and+neurons%5BTitle%5D)+AND+%22Proc+Natl+Acad+Sci+U+S+A%22%5BJournal%5D)">Deficits in human trisomy 21 iPSCs and neurons.</a> Proc Natl Acad Sci U S A. 110 (24), 9962-9967 (2013).</li>
<li>Meharena, H. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Down+syndrome-induced+senescence+disrupts+the+nuclear+architecture+of+neural+progenitors%5BTitle%5D)+AND+%22Cell+Stem+Cell%22%5BJournal%5D)">Down syndrome-induced senescence disrupts the nuclear architecture of neural progenitors.</a> Cell Stem Cell. 29 (1), 116-130.e7 (2022).</li>
<li>Sharma, V., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Biphasic+cell+cycle+defect+causes+impaired+neurogenesis+in+Down+syndrome%5BTitle%5D)+AND+%22Front+Genet%22%5BJournal%5D)">Biphasic cell cycle defect causes impaired neurogenesis in Down syndrome.</a> Front Genet. 13, 1007519(2022).</li>
<li>Maclean, G. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Altered+hematopoiesis+in+trisomy+21+as+revealed+through+in+vitro+differentiation+of+isogenic+human+pluripotent+cells%5BTitle%5D)+AND+%22Proc+Natl+Acad+Sci+USA%22%5BJournal%5D)">Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells.</a> Proc Natl Acad Sci USA. 109 (43), 17567-17572 (2012).</li>
<li>Nehra, S., Sharma, V., Umrani, M., Singhal, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Generation+of+integration-free+Down+syndrome+and+isogenic+euploid+human+induced+pluripotent+stem+cells%5BTitle%5D)+AND+%22Stem+Cell+Res%22%5BJournal%5D)">Generation of integration-free Down syndrome and isogenic euploid human induced pluripotent stem cells.</a> Stem Cell Res. 67, 103041(2023).</li>
<li>Yu, P. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Dorsomorphin+inhibits+BMP+signals+required+for+embryogenesis+and+iron+metabolism%5BTitle%5D)+AND+%22Nat+Chem+Biol%22%5BJournal%5D)">Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.</a> Nat Chem Biol. 4 (1), 33-41 (2008).</li>
<li>Shi, Y., Kirwan, P., Smith, J., Robinson, H. P., Livesey, F. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+cerebral+cortex+development+from+pluripotent+stem+cells+to+functional+excitatory+synapses%5BTitle%5D)+AND+%22Nat+Neurosci%22%5BJournal%5D)">Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses.</a> Nat Neurosci. 15 (3), 477-486 (2012).</li>
<li>Espuny-Camacho, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Pyramidal+neurons+derived+from+human+pluripotent+stem+cells+integrate+efficiently+into+mouse+brain+circuits+in+vivo%5BTitle%5D)+AND+%22Neuron%22%5BJournal%5D)">Pyramidal neurons derived from human pluripotent stem cells integrate efficiently into mouse brain circuits in vivo.</a> Neuron. 77 (3), 440-456 (2013).</li>
<li>Gaspard, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Generation+of+cortical+neurons+from+mouse+embryonic+stem+cells%5BTitle%5D)+AND+%22Nat+Protoc%22%5BJournal%5D)">Generation of cortical neurons from mouse embryonic stem cells.</a> Nat Protoc. 4 (10), 1454-1463 (2009).</li>
</ol>

The authors have no conflict of interest to disclose.

In this work, an efficient undirected monolayer cortical neurodifferentiation protocol for an isogenic pair of Euploid hiPSCs and DS hiPSCs is described. Since the cells are grown as monolayers, they are more exposed to culture conditions, which is not possible to the same extent as using embryoid bodies for differentiating iPSCs, which are generally used in other protocols14,16. While the utility of organoid systems is growing, monolayer-based neural differentia...

Down syndrome (DS), or trisomy 21, is the most common chromosomal abnormality and the leading cause of intellectual disability (ID)1. Impaired neurogenesis during DS fetal development is one of the causes of intellectual disability in DS2. Human DS fetal studies show a reduction in brain weight and volume, reduced neurons, increased astrocytes3,4, and abnormal distribution of neurons in layers II and IV5,6. Additionally, the second phase of cortical development, i.e., the emergence of lamination, is both delayed and disorganized in DS7.
Neurodevelopment defects in DS have been studied mostly using mice models of DS such as Ts65Dn, Ts1Rhr, and Ts1cje8. However, these mice models were not able to fully recapitulate various phenotypes observed in DS studies due to physiological and developmental differences between mice and humans9, which led to failed clinical trials10. The invention of induced pluripotent stem cells11,12 provided an opportunity to model Down syndrome neurological impairment using cells derived directly from individuals with DS. However, earlier attempts to model DS neurodevelopmental defects using human iPSCs met with inconsistent results and could not fully explain neurodevelopmental defects observed in DS fetal brain sections13,14,15,16. For instance, a report published by Shi et al. found DS-related Alzheimer&#39;s phenotypes but reported no difference in DS neurogenesis compared to euploid controls15. Similarly, Weick et al. reported reduced synaptic activity but normal neurogenesis in DS compared to euploid controls16. However, normal neurogenesis in DS reported in these publications was not consistent with observation from DS fetal brain sections. Later, a report by Hibaoui et al. reported reduced neurogenesis in DS, which was consistent with the observation from the DS fetal brain section14. However, this report and another recent report described the reduced proliferation of DS NPCs as the cause of reduced neurogenesis in DS14,17. However, only reduced proliferation of DS NPCs could not explain increased astroglial cells and delayed emergence of lamination during DS fetal brain development.
In recently published work, a human iPSC-based DS-impaired neurogenesis model showing reduced neurogenesis was developed. This model found that impaired neurogenesis in DS is due to biphasic cell cycle defects during the neurogenic stage (the stage during which neural progenitor cells are generated from pluripotent stem cells). During the first phase in the neurogenic stage, DS NPCs exhibit reduced proliferation compared to isogenic euploid neural cells, followed by increased proliferation of DS NPCs compared to isogenic euploid cells in the late phase of the neurogenic stage18.
In this manuscript, a step-by-step detailed protocol for the differentiation of Down syndrome hiPSCs and its isogenic euploid hiPSCs into cortical neurons has been described. The overall goal of this method is to provide a detailed, step-by-step protocol for differentiating a pair of DS hiPSCs and its isogenic euploid hiPSCs into cortical neurons with a focus on modeling the neurogenesis defects associated with DS. This protocol is designed to offer a robust and reproducible system for investigating the cellular and molecular mechanisms underlying abnormalities causing DS-impaired neurogenesis.
The rationale behind the development of this protocol is to allow the differentiation of pluripotent stem cells into cortical neurons by utilizing principles of developmental neurobiology, thereby allowing the identification of phenotypes that arise due to disease/disorder. It aimed to take a minimalistic approach to neural differentiation of iPSCs by avoiding compounds like cAMP or DAPT, which may mask disease phenotypes arising due to defects in the Ca++ channel or NOTCH pathway, respectively. Similarly, the use of Ascorbic acid, BDNF, and GDNF was also avoided, which may mask other neurological disease-related phenotypes by potentiating neurogenesis.
The advantages of this technique over alternative methods lie in providing robust recapitulation of neurological phenotypes observed in DS fetal brain sections. Of note, compared to mouse models, the human iPSC-based system eliminates cross-species differences, providing a more relevant model for studying human-specific neurodevelopmental processes9 but until now has failed to recapitulate DS impaired neurogenesis observed in DS fetal stages onwards. Further, the use of isogenic pairs of hiPSCs reduces variability and enhances the reliability of observed phenotypic differences. This protocol will be of particular interest to researchers studying neurodevelopmental disorders and human neurogenesis. It is especially relevant for those seeking to model human-specific aspects of DS or those interested in developing therapeutic interventions targeting the neurogenesis defects associated with trisomy 21.

<table><tbody><tr><td>&lt;strong&gt;MEF medium:&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>DMEM High Glucose</td><td>Gibco</td><td>11965-092</td><td></td></tr><tr><td>FBS</td><td>VWR</td><td>97068-085</td><td>10% final concentration</td></tr><tr><td>Non-Essential Amino Acids</td><td>Hyclone</td><td>SH30238.01</td><td>1X final concentration</td></tr><tr><td>Penicillin/Streptomycin</td><td>Hyclone</td><td>SV30010</td><td>1X final concentration</td></tr><tr><td>&amp;beta;-Mercaptoethanol</td><td>Gibco</td><td>21985-023</td><td>1X final concentration</td></tr><tr><td>&lt;strong&gt;hiPSC medium:&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Knockout DMEM/F12</td><td>Gibco&amp;nbsp;</td><td>12660-012</td><td></td></tr><tr><td>Knockout Serum Replacement (KOSR)</td><td>Gibco</td><td>10828-028</td><td>20% final concentration</td></tr><tr><td>Non-Essential Amino Acids</td><td>Hyclone</td><td>SH30238.01</td><td>1X final concentration</td></tr><tr><td>Glutamax</td><td>Gibco&amp;nbsp;</td><td>35050061</td><td>1X final concentration</td></tr><tr><td>Penicillin/Streptomycin</td><td>Hyclone</td><td>SV30010</td><td>1X final concentration</td></tr><tr><td>&amp;beta;-Mercaptoethanol (1000X)</td><td>Gibco</td><td>21985-023</td><td>1X final concentration</td></tr><tr><td>&lt;strong&gt;DDM medium:&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Knockout DMEM/F12</td><td>Gibco&amp;nbsp;</td><td>12660-012</td><td></td></tr><tr><td>Non-Essential Amino Acids</td><td>Hyclone</td><td>SH30238.01</td><td>1X final concentration</td></tr><tr><td>Glutamax</td><td>Gibco&amp;nbsp;</td><td>35050061</td><td>1X final concentration</td></tr><tr><td>Penicillin/Streptomycin</td><td>Hyclone</td><td>SV30010</td><td>1X final concentration</td></tr><tr><td>Albumax (10%)</td><td>Invitrogen&amp;nbsp;</td><td>11020-021</td><td>0.5 X of 10% Albumax is final concentration</td></tr><tr><td>&lt;strong&gt;NPC medium:&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>DDM medium</td><td></td><td></td><td></td></tr><tr><td>N2 Supplement</td><td>Gibco&amp;nbsp;</td><td>17502048</td><td>1X final concentration</td></tr><tr><td>B-27 Supplement (50X), minus vitamin A</td><td>Gibco&amp;nbsp;</td><td>12587010</td><td>1X final concentration</td></tr><tr><td>&lt;strong&gt;Neural Differentiation medium (ND):&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>DDM medium</td><td></td><td></td><td>1/2 of volume</td></tr><tr><td>Neurobasal Medium</td><td>Gibco&amp;nbsp;</td><td>21103-049</td><td>1/2 of volume</td></tr><tr><td>N2 Supplement</td><td>Gibco&amp;nbsp;</td><td>17502048</td><td>0.5 X final concentration</td></tr><tr><td>B-27 Supplement (50X)</td><td>Gibco&amp;nbsp;</td><td>17504044</td><td>0.5 X final concentration</td></tr><tr><td>Glutamax</td><td>Gibco&amp;nbsp;</td><td>35050061</td><td>1X of Neurobasal medium</td></tr><tr><td>Penicillin/Streptomycin</td><td>Hyclone</td><td>SV30010</td><td>1X of Neurobasal medium</td></tr><tr><td>&lt;strong&gt;Antibodies and reagents for immunostaining:&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Paraformaldehyde</td><td>Sigma-Aldrich</td><td>158127-500G</td><td>4%</td></tr><tr><td>DPBS, no calcium, no magnesium</td><td>Sigma-Aldrich</td><td>D5652</td><td></td></tr><tr><td>Triton-X-100 Solution</td><td>Sigma-Aldrich</td><td>X100-500ML</td><td>0.20%</td></tr><tr><td>BSA</td><td>Hyclone</td><td>A7979-50ML</td><td>1.00%</td></tr><tr><td>Purified anti-tubulin &amp;beta;-3 (TUBB3) (TUJ1)</td><td>BioLegend</td><td>801202</td><td>1:500 dilution</td></tr><tr><td>Donkey anti-Mouse IgG (H+L) Secondary Antibody, Alexa fluor 594 conjugate</td><td>Life Tech Invitrogen&amp;nbsp;</td><td>A21203</td><td>1:250 dilution</td></tr><tr><td>Purified Mouse-Anti-Human Ki67</td><td>BD Pharmingen</td><td>550609</td><td>1:100 dilution</td></tr><tr><td>Purified anti-PAX6</td><td>BioLegends</td><td>901302</td><td>1:100 dilution</td></tr><tr><td>Alexa fluor 488 Donkey (anti-rabbit)</td><td>Life Tech Invitrogen&amp;nbsp;</td><td>A21206</td><td>1:250 dilution</td></tr><tr><td>DAPI Solution (5 mg/mL)</td><td>Sigma</td><td>D9542</td><td>1:1000 dilution</td></tr><tr><td>&lt;strong&gt;Others&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Cell detachment solution (Accutase)&amp;nbsp;</td><td>Gibco&amp;nbsp;</td><td>A11105-01</td><td>Ready to use working solution</td></tr><tr><td>Rock inhibitor (RI)&amp;nbsp;</td><td>Sellechckem&amp;nbsp;</td><td>Y27632</td><td>10 mM/ml final concentration</td></tr><tr><td>Dorsomorphin&amp;nbsp;</td><td>Sellechckem&amp;nbsp;</td><td>S7306</td><td>0.125 nM/ml final concentration</td></tr><tr><td>DPBS with calcium and magnisium (DPBS+ Ca, Mg)</td><td>Gibco&amp;nbsp;</td><td>14040133</td><td>Ready to use working solution</td></tr><tr><td>DPBS without calcium and magnisium</td><td>Gibco&amp;nbsp;</td><td>14190136</td><td>Ready to use working solution</td></tr><tr><td>Gelatin Type A</td><td>Sigma&amp;nbsp;</td><td>G2500-100G</td><td>0.10%</td></tr><tr><td>hESC-qualified basement membrane matrix (Matrigel GFR)&amp;nbsp;</td><td>Corning&amp;nbsp;</td><td>356230</td><td>1 mg stock vial diluted 1:240</td></tr><tr><td>Trypsin 0.05%</td><td>Gibco</td><td>25300054</td><td></td></tr><tr><td>Trypan Blue</td><td>Gibco</td><td>15250-061</td><td>0.40%</td></tr><tr><td>Basic Fibrablast Growth Factor (bFGF)</td><td>Peprotech&amp;nbsp;</td><td>100-18B</td><td>25 ng/ml final concentration</td></tr><tr><td>Collagenase&amp;nbsp;</td><td>Gibco&amp;nbsp;</td><td>17104-019</td><td>1mg/ml final concentration</td></tr></tbody></table>

in vitro modeling of down syndrome neurogenesis using human-induced pluripotent stem cells

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells

Down syndrome (DS), caused by an extra copy of chromosome 21, is a leading cause of intellectual disability. One of the key factors contributing to this intellectual disability is impaired neurogenesis observed from fetal stages onwards. To study these neurodevelopmental abnormalities, human-induced pluripotent stem cells (hiPSCs) generated using cells obtained from DS patients provide a valuable and relevant model. Here, a comprehensive protocol is described for recapitulating DS-impaired neurogenesis observed during DS fetal stages. This protocol utilizes a pair of DS-hiPSCs having three copies of chromosome 21 and its isogenic euploid hiPSCs having two copies of chromosome 21. Importantly, the protocol described here recapitulates DS-impaired neurogenesis and found that biphasic cell cycle defect, i.e., reduced proliferation of DS neural progenitor cells (NPC) during the early phase of the neurogenic stage followed by increased proliferation of DS NPC during the late phase of the neurogenic stage is the cause of DS impaired neurogenesis. Increased proliferation of DS NPC during the late phase of the neurogenic stage leads to delayed exit from the cell cycle, causing reduced generation of post-mitotic neurons from DS NPCs. This protocol includes detailed steps for the maintenance of hiPSCs, their differentiation into neural lineages displaying biphasic cell cycle defect during the neurogenic stage, and the subsequent validation of reduced neural differentiation in DS cells. By following this methodology, researchers can create a robust experimental system that mimics the neurodevelopmental conditions of DS, enabling them to explore the specific alterations in brain development caused by trisomy 21.

Singularized human iPSCs were seeded onto qualified matrix-coated dishes as single-cell suspensions, and differentiation was initiated by removing bFGF. To inhibit non-ectodermal differentiation, Dorsomorphin, a BMP signaling inhibitor, was added from DIV 2-1821. For further differentiation of progenitor cells from the neurogenic stage, single-cell suspensions were replated at low density on the qualified matrix (Figure 1) for an additional 6-10 weeks to observe early...

This protocol outlines a methodology for recapitulating Down syndrome (DS) impaired neurogenesis using DS human iPSCs. The protocol identified biphasic cell cycle defect as the cause of impaired neurogenesis in Down syndrome. It provides a robust platform for understanding cellular and molecular mechanisms underlying the abnormal neurogenesis associated with DS.

Down syndrome (DS), caused by an extra copy of chromosome 21, is a leading cause of intellectual disability. One of the key factors contributing to this ...

in-vitro-modeling-down-syndrome-neurogenesis-using-human-induced

Research

JoVE Journal

Neuroscience

A simple and reliable method on isolation and culture of neural stem cells from discarded human fetal cortical tissue is described.  Cultures derived from known human neurological disorders can be used for characterization of pathological cellular and molecular processes, as well as provide a platform to assess pharmacological efficacy.

Generation of Neural Stem Cells from Discarded Human Fetal Cortical Tissue

This procedure yields telencephalic neurons by going through checkpoints which are similar to those observed during human development. The cells are allowed to spontaneously differentiate, are exposed to factors which push them towards the neural lineage, are isolated, and are plated onto coverslips to allow for terminal differentiation and maturation.

The Specification of Telencephalic Glutamatergic Neurons from Human Pluripotent Stem Cells

We, based on knowledge from developmental biology and published research, developed an optimized protocol to efficiently generate A9 midbrain dopaminergic neurons from both human embryonic stem cells and human induced pluripotent stem cells, which would be useful for disease modeling and cell replacement therapy for Parkinson’s disease.

Directed Dopaminergic Neuron Differentiation from Human Pluripotent Stem Cells

This protocol describes how neural progenitor cells can be differentiated from human induced pluripotent stem cells, in order to yield a robust and replicative neural cell population, which may be used to identify the developmental pathways contributing to disease pathogenesis in many neurological disorders.

A Guide to Generating and Using hiPSC Derived NPCs for the Study of Neurological Diseases

Modeling human brain development has been hindered due to the unprecedented complexity of neural epithelial tissue. Here, a method for the robust generation of brain organoids to delineate early events of human brain development and to model microcephaly in vitro is described.

Generation of iPSC-derived Human Brain Organoids to Model Early Neurodevelopmental Disorders

Here we report a protocol to develop a three-dimensional (3-D) system from human induced-pluripotent stem cells (hiPSCs) called the serum free embryoid body (SFEB). This 3-D model can be used like an organotypic slice culture to model human cortical development and for the physiological interrogation of developing neural circuits.

Developing HiPSC Derived Serum Free Embryoid Bodies for the Interrogation of 3-D Stem Cell Cultures Using Physiologically Relevant Assays

We describe a protocol to reprogram human skin-derived fibroblasts into induced Neuronal Progenitor Cells (iNPCs), and their subsequent differentiation into induced Astrocytes (iAs). This method leads to fast and reproducible generation of iNPCs and iAs in large quantities.

In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes

This protocol describes the generation of integration free iPSCs from fetal tissue fibroblasts through delivery of episomal plasmids by nucleofection followed by description of methods used for iPSC characterization and neuronal differentiation.

Generation of Induced Pluripotent Stem Cells from Turner Syndrome (45XO) Fetal Cells for Downstream Modelling of Neurological Deficits Associated with the Syndrome

We describe a method for differentiating spinal cord human induced pluripotent-derived astrocytes and neurons and their co-culture for electrophysiological recording.

Establishment of an Electrophysiological Platform for Modeling ALS with Regionally-Specific Human Pluripotent Stem Cell-Derived Astrocytes and Neurons

The present protocol explains the generation of a 2D monolayer of cerebellar cells from induced pluripotent stem cells for investigating the early stages of cerebellar development.

Modeling Human Cerebellar Development In Vitro in 2D Structure

Explore in vitro modeling of Down syndrome neurogenesis using human iPSCs. This protocol reveals biphasic cell cycle defects causing impaired neuron generation, offering insights for therapeutic development.

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells

Explore More Videos